Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial

This randomized withdrawal study assessed relapse prevention with vilazodone in adults with major depressive disorder. After 20 weeks of open-label treatment with vilazodone 40 mg/day, responders were randomized (1 : 1 : 1) to 28 weeks of double-blind, fixed-dose treatment with vilazodone 20 mg/day,...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Gommoll, Carl, Migliore, Raffaele, Chen, Changzheng, Chang, Cheng-Tao, Aguirre, Michelle, Thase, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166708/
https://www.ncbi.nlm.nih.gov/pubmed/30044247
http://dx.doi.org/10.1097/YIC.0000000000000236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166708/
https://www.ncbi.nlm.nih.gov/pubmed/30044247
http://dx.doi.org/10.1097/YIC.0000000000000236

Ejemplares similares